Heart failure & cardiomyopathies
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs
Authors' conclusion
Utilization rates of SGLT2 inhibitors are low in patients with ASCVD, HF, and T2DM, with high residual facility-level variation.
Study context
- Population
- Patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) and T2DM seen by a primary care provider in the Veterans Affairs health care system, 2020130 VA facilities
- Participants
- 105,799 patients
- Outcome
- Utilization of SGLT2 inhibitors and facility-level variation (median rate ratio)
Methodological detailsmulticentre, nationwide Veterans Affairs health care system
- Multicentre
- Nationwide Veterans Affairs health care system
Main finding
As reported in the abstract
Received SGLT2 inhibitors
14.6%
Facility-level variation, adjusted median rate ratio
1.55
95% CI 1.46–1.64
Residual difference in SGLT2 inhibitor use among similar patients at 2 random facilities
55%
Observational data: associations, not effects.
Further findings
Characteristics of SGLT2 inhibitor recipients
- Recipients were younger men with higher hemoglobin A1c and eGFR, more likely to have HFrEF and ischemic heart disease
Original publication
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. Published 17 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →